Skip to main content

Orthobiologics Market Size to Hit USD 12.33 billion by 2029

According to Fortune Business Insights™, the global Orthobiologics Market size is expected to reach USD 12.33 billion by 2029, at a CAGR of 5.4% during the forecast period, 2022-2029

Pune, India, Sept. 19, 2022 (GLOBE NEWSWIRE) — The global orthobiologics market size was valued at USD 7.63 billion in 2021. The market is expected to grow from USD 8.56 billion in 2022 to USD 12.33 billion by 2029, exhibiting a CAGR of 5.4% during the forecast period. Increasing adoption of stem-cell allografts and rapid adoption of viscosupplements for delayed total knee replacements are expected to foster the industry’s growth. Fortune Business Insights™ provides this information in its report titled “Orthobiologics Market, 2022-2029.

Key Industry Development

  • October 2021- AlloSource announced its novel AlloMend Extra-Large (XL) Acellular Dermal Matrix (ADM) to expand its product offerings.


Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/orthobiologics-market-100173


Report Scope

Report CoverageDetails
Forecast Period2022 to 2029
Forecast Period 2022 to 2029 CAGR5.4%
2029 Value ProjectionUSD 12.33 Billion
Base Year2021
Market Size in 2022USD 8.56 Billion
Historical Data for2018 to 2020
No. of Pages181


Drivers and Restraints

Rising Orthopedic Injuries to Bolster the Market’s Progress

Orthobiologics are prepared using substances naturally obtained from the body, enhancing the healing process. Increasing orthopedic injuries are expected to foster the product demand. Furthermore, rising incidences of osteoporosis disorders are expected to foster the demand for effective healthcare services. Moreover, there is an increasing prevalence of hip and backbone fractures. Also, increasing product launches by companies is expected to elevate this industry’s growth. For example, Royal Biologics announced its novel MAGNUS in January 2020. These factors are likely to drive the orthobiologics market growth.

However, issues regarding bone morphogenetic proteins and clinical limitations are likely to hinder the market’s progress.


Click here to get the short-term and long-term impact of COVID-19 on this market.

Please visit: https://www.fortunebusinessinsights.com/industry-reports/orthobiologics-market-100173


Regional Insights

Rapid Biologics Adoption for Bone-related Disorders & Injuries to Propel Market Growth in North America

North America is projected to dominate the orthobiologics market share due to rapid biologics adoption for bone-related disorders & injuries. The market in North America was valued at USD 3.65 billion in 2021 and is expected to gain a huge portion of the global market in the coming years. Further, the presence of a huge patient population is expected to bolster the industry’s growth.

In Europe, rising favorable health policies are expected to bolster the adoption of orthobiologics. Furthermore, the rising focus of companies on introducing new products is expected to elevate the industry’s growth. 

COVID-19 Impact:

Decreasing Patient Volume Hindered Market Progress

This market was negatively affected during the COVID-19 pandemic due to decreasing patient volume. The sudden patient spike led to a lack of in-patient visits, hindering the industry’s growth. Furthermore, restrictions on manufacturing led to a lack of resources available to produce effective products and services. Moreover, the restrictions on transport and travel led to a lack of raw materials required to produce orthobiologics. However, the post COVID-19 relaxations allowed manufacturers to elevate their production capacities and enhance their sales.


Quick Buy –  Orthobiologics Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100173


Segmentation

Viscosupplements Segment to Dominate Owing to Rising Prevalence of Degenerative Arthritis

By product type, the market is segmented into viscosupplements, bone growth factors, Demineralized Bone Matrix (DBM), synthetic bone substitutes, cellular allograft, allografts, and others. The viscosupplements segment is expected to dominate attributable to the rising prevalence of degenerative arthritis

Spinal Fusion Segment to Hold Major Market Share Owing to Rising Spinal Fusion Treatments

Based on application, this market is classified into spinal fusion, maxillofacial & dental, soft tissue repair, reconstructive & fracture surgery, and others. The spinal fusion segment is expected to hold a major market share due to rising spinal fusion treatments.

Hospitals & ASCs Segment to Dominate Owing to Huge Patient Volume

As per end-user, the market is categorized into hospitals & Ambulatory Surgical Centers (ASCs), specialty clinics, and others. The hospitals & ASCs segment is expected to dominate attributable to huge patient volumes.

Geographically, the market is clubbed into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Market SegmentationBy Product Type

  • Viscosupplements
  • Bone Growth Factors
  • Demineralized Bone Matrix (DBM)
  • Synthetic Bone Substitutes
  • Cellular Allograft
  • Allografts
  • Others
By Application

  • Spinal Fusion
  • Maxillofacial & Dental
  • Soft Tissue Repair
  • Reconstructive & Fracture Surgery
  • Others
By End-user

  • Hospitals & Ambulatory Surgical Centers (ASCs)
  • Specialty Clinics
  • Others


Report Coverage

The report provides a detailed analysis of the top segments and the latest trends in the market. It comprehensively discusses the driving and restraining factors and the impact of COVID-19 on the market. Additionally, it examines the regional developments and the strategies undertaken by the market’s key players.

List of Key Players Profiled in the Report

  • Medtronic (Ireland)
  • Zimmer Biomet (U.S.)
  • DePuy Synthes (Johnson & Johnson Services, Inc.) (U.S.)
  • Stryker (U.S.)
  • Anika Therapeutics, Inc. (U.S.)
  • SeaSpine (U.S.)
  • Bioventus (U.S.)
  • RTI Surgical (U.S.)
  • MTF Biologics (U.S.)
  • Arthrex, Inc. (U.S.)
  • Smith & Nephew (U.K.)


Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/orthobiologics-market-100173


Major Table of Content:

  • Introduction
    • Research Scope
    • Market Segmentation
    • Research Methodology
    • Definitions and Assumptions
  • Executive Summary
  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
    • Market Trends
  • Key Insights
    • Epidemiology of Clinical Indications
    • Regulatory Scenario for Key Countries
    • Number of Key Spinal Fusion Procedures in the U.S., by Type, 2021
    • New Product Launches
    • Key Industry Developments (Mergers, Acquisitions, and Partnership)
    • Impact of COVID-19 on the Market
  • Global Orthobiologics Market Analysis, Insights and Forecast, 2018-2029
    • Market Analysis, Insights and Forecast – By Product Type
      •  Viscosupplements
      •  Bone Growth Factors
      •  Demineralized Bone Matrix (DBM)
      •  Synthetic Bone Substitutes
      •  Cellular Allograft
      •  Allografts
      •  Others
    • Market Analysis, Insights and Forecast – By Application
      •  Spinal Fusion
      •  Maxillofacial & Dental
      •  Soft Tissue Repair
      •  Reconstructive & Fracture Surgery
      •  Others
    • Market Analysis, Insights and Forecast – By End-user
      •  Hospitals & Ambulatory Surgical Centers (ASCs)
      •  Specialty Clinics
      •  Others
    • Market Analysis, Insights and Forecast – By Region
      •  North America
      •  Europe
      •  Asia Pacific
      •  Latin America
      •  Middle East & Africa
  • North America Orthobiologics Market Analysis, Insights and Forecast, 2018-2029
    • Market Analysis, Insights and Forecast – By Product Type
      •  Viscosupplements
      •  Bone Growth Factors
      •  Demineralized Bone Matrix (DBM)
      •  Synthetic Bone Substitutes
      •  Cellular Allograft
      •  Allografts
      •  Others
    • Market Analysis, Insights and Forecast – By Application
      •  Spinal Fusion
      •  Maxillofacial & Dental
      •  Soft Tissue Repair
      •  Reconstructive & Fracture Surgery
      •  Others
    • Market Analysis, Insights and Forecast – By End-user
      •  Hospitals & Ambulatory Surgical Centers (ASCs)
      •  Specialty Clinics
      •  Others
    • Market Analysis, Insights and Forecast – By Country
      •  U.S.
        • By Application
      •  Canada
        • By Application

Continued…           


Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/orthobiologics-market-100173


About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

Pune – 411045, Maharashtra, India.

Phone:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.